Thus far, the promise of precision medicine has been directed largely toward the field of oncology in terms of recommending personalized treatments based on molecular diagnostics tests. But ...

Findings being presented in San Francisco show which patients may be able to stop anti-TNF therapy, and which ones will do well with conventional drugs as second-line treatment. A test that predicts ...

Rheumatoid arthritis (RA) is classified as seropositive or seronegative based on the presence of specific antibodies in the blood, which can influence the severity of symptoms and treatment response.

Equipped with a blood test capable of predicting an individual’s response—or lack thereof—to the world’s largest drug class, Scipher Medicine is on its way to cracking the code of rheumatoid arthritis ...

What is rheumatoid arthritis (RA) and how has it traditionally been diagnosed? Rheumatoid arthritis (RA) is an autoimmune disorder that can cause debilitating joint damage. In cases of RA, the immune ...

Crescendo Bioscience, creators of the Vectra DA blood test to predict the progression of rheumatoid arthritis (RA), is gaining market share in the United States, with its new parent company, Myriad ...

Seven years ago, Northeastern graduate Susan Dina Ghiassian was the first employee of Scipher Medicine Corp., a precision medicine company co-founded by Northeastern professor Albert-László Barabási.

Researchers have identified several cytokines, cytokine-related factors, and chemokines that increase significantly prior to rheumatoid arthritis disease onset. These findings confirm those of earlier ...

One of the many challenges of a rheumatoid arthritis diagnosis is the condition’s variability from patient to patient and over time. This unpredictability also impacts the effectiveness of drugs used ...

Rheumatoid arthritis can be tricky to diagnose because of the broad range of symptoms associated with the disease. Joint stiffness and inflammation are key signs of rheumatoid arthritis, though they ...